# Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

> **NCT04657081** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Taiho Oncology, Inc.** · enrollment: 101 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Decitabine and Cedazuridine (ASTX727)
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04657081
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-09
- **Primary completion:** 2024-09-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04657081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04657081, "Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT04657081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*